Key result
High-dose continuous intravenous infusion fluorouracil was associated with a 7.6% incidence of cardiac events (95% CI, 4.9-10.3%), with a 2.2% lethality rate.
Why the study?
What is the incidence of cardiotoxicity in patients receiving high-dose continuous intravenous infusion fluorouracil?
Population
367 patients receiving first-cycle high-dose continuous intravenous infusion fluorouracil for primary tumors…
Design
Cohort
Authors
Loading...
Supports cardiac monitoring during high-dose 5FU-CIV; leaves open prospective validation of risk factors and mitigation.
Observational (n=367)
What is the incidence of cardiotoxicity in patients receiving high-dose continuous intravenous infusion fluorouracil?
High-dose continuous infusion fluorouracil is associated with a 7.6% incidence of cardiotoxicity, including severe events and a 2.2% lethality rate, highlighting the need for careful cardiac monitoring.
Forni et al. (1992) conducted an observational in Cancer (n=367). High-dose continuous intravenous infusion fluorouracil (5FU-CIV) was evaluated on 5FU-induced cardiac events (95% CI 4.9-10.3). High-dose continuous intravenous infusion fluorouracil was associated with a 7.6% incidence of cardiac events (95% CI, 4.9-10.3%), with a 2.2% lethality rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: